Home > Oncology > ASCO 2020 > T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported

T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported

Findings from the primary analysis of the KAITLIN trial suggest that replacement of adjuvant taxane with trastuzumab emtansine (T-DM1) does not improve survival or safety for patients with HER2-positive early-stage breast cancer [1]. However, both treatments demonstrated outstanding long-term invasive disease–free survival (iDFS) in a high-risk population. Study author Nadia Harbeck, MD, PhD, of the University of Munich, in Germany, and West German Study Group, presented these data during the ASCO20 Virtual Scientific Program.

HER2-positive early-stage breast cancer is a particularly aggressive, and neoadjuvant chemotherapy plus HER2-targeted therapy is the standard of care. Despite its efficacy, patients remain at increased risk of recurrence, mortality, and taxane-related toxicity, making it critical to optimize HER2-targeted treatment and determine who might benefit the most.

“In 2005, we were lucky to have one HER2-targeted therapy to combine wi...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on